Johnson & Johnson Analyst Price Targets

Wall Street analyst price targets and consensus rating for Johnson & Johnson (JNJ).

Price Target Range — 8 Quarters

Analyst Consensus — 17 Analysts

11Buy

6Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$265Upside to Avg. PT+4.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$294→$292
Oct 14, 2026	Leerink Partners	David Risinger	PT Cut	Outperform	$276→$272
Oct 14, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Overweight	$282→$275
Oct 14, 2026	RBC Capital	Trung Huynh	PT Cut	Outperform	$290→$280
Oct 7, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$287
Oct 6, 2026	RBC Capital	Trung Huynh	PT Raise	Outperform	$287→$290
Oct 5, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$298→$303
Sep 29, 2026	JP Morgan	Chris Schott	PT Raise	Neutral	$270→$285
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$290→$320
Sep 2, 2026	UBS	Michael Yee	PT Raise	Buy	$280→$320
Aug 6, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$270→$287
Aug 3, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$272→$282
Jul 17, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$270
Jul 16, 2026	Raymond James	Jayson Bedford	PT Raise	Outperform	$258→$265
Jul 16, 2026	RBC Capital	Shagun Singh	Maintained	Outperform	$287
Jul 16, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$263→$272
Jul 16, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$284→$294
Jul 13, 2026	TD Cowen	Michael Nedelcovych	PT Raise	Buy	$250→$300
Jul 13, 2026	RBC Capital	Shagun Singh	PT Raise	Outperform	$265→$287
Jul 10, 2026	B of A Securities	Tim Anderson	PT Raise	Neutral	$254→$263

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292

Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and lowers the price target from $294 to $292.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $272

Leerink Partners analyst David Risinger maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target from $276 to $272.

Benzinga Newsdesk

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

Johnson & Johnson posted upbeat Q3 results; analysts stayed bullish, though RBC cut its target and noted mixed product and MedTech trends.

Priya Nigam

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Johnson & Johnson beat Q3 estimates and raised full-year guidance; sales rose 5.9%, EPS fell 7.5%. Analysts trimmed price targets.

Avi Kapoor

PRO
Wells Fargo Maintains Overweight on Johnson & Johnson, Lowers Price Target to $275

Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and lowers the price target from $282 to $275.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $280

RBC Capital analyst Trung Huynh maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target from $290 to $280.

Benzinga Newsdesk

Johnson & Johnson

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Johnson & Johnson Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292

PRO
Leerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $272

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

PRO
Wells Fargo Maintains Overweight on Johnson & Johnson, Lowers Price Target to $275

PRO
RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $280

People Also Watch

People Also Watch

Johnson & Johnson

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Johnson & Johnson Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292

PROLeerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $272

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

PROWells Fargo Maintains Overweight on Johnson & Johnson, Lowers Price Target to $275

PRORBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $280

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292

PRO
Leerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $272

PRO
Wells Fargo Maintains Overweight on Johnson & Johnson, Lowers Price Target to $275

PRO
RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $280